Trial abstract · §3
CELIAC-PH2B — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in a coeliac disease symptom measure during gluten exposure | A symptom effect at the lowest dose only, with no effect at higher doses | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Larazotide acetate from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Headache | — | — | Reported at similar rates to placebo |
| Nasopharyngitis | — | — | Similar to placebo |
| Urinary tract infection | — | — | Reported |
| Overall safety profile | — | — | Comparable to placebo across the programme, consistent with negligible systemic exposure |
Compound Evidence Institute · CEI-TR-0129/3 · https://compoundevidence.com/trials/celiac-ph2b/results/ · retrieved 30 July 2026